Literature DB >> 16929325

Comparing antibody and small-molecule therapies for cancer.

Kohzoh Imai1, Akinori Takaoka.   

Abstract

The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16929325     DOI： 10.1038/nrc1913

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  216 in total

Review 1.  Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Authors:  Michael J Demeure; Kimberly J Bussey; Lawrence S Kirschner
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Authors:  Yayun Liang; Cynthia Besch-Williford; Indira Benakanakere; Philip E Thorpe; Salman M Hyder
Journal:  Breast Cancer Res Treat       Date:  2010-03-27       Impact factor: 4.872

Review 3.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

4.  In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.

Authors:  Prashant Chaudhari; Sanjay Bari
Journal:  Mol Divers       Date:  2015-09-28       Impact factor: 2.943

5.  Dynamics of targeted cancer therapy.

Authors:  Ivana Bozic; Benjamin Allen; Martin A Nowak
Journal:  Trends Mol Med       Date:  2012-05-15       Impact factor: 11.951

6.  Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.

Authors:  Akihiro Tomita; Junji Hiraga; Hitoshi Kiyoi; Manabu Ninomiya; Takumi Sugimoto; Masafumi Ito; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

7.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

8.  Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.

Authors:  Patrick Ho; Christopher Ede; Yvonne Y Chen
Journal:  ACS Synth Biol       Date:  2017-05-22       Impact factor: 5.110

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

10.  Bayesian clustering and feature selection for cancer tissue samples.

Authors:  Pekka Marttinen; Samuel Myllykangas; Jukka Corander
Journal:  BMC Bioinformatics       Date:  2009-03-18       Impact factor: 3.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.